ExpansionJul 29, 2026, 04:37 PM
Splash Beverage Expands CannEpil to Veterinary Therapeutics
AI Summary
Splash Beverage Group, Inc. expanded its exclusive global license for CannEpil® with Argent BioPharma Limited to include veterinary therapeutic applications. This creates a second regulated pharmaceutical development platform, alongside its existing human program. The amendment grants Splash exclusive worldwide rights for CannEpil in veterinary medicine, with an initial focus on companion-animal oncology and chronic pain management, particularly for canine indications. The company will pay a 10% royalty on net revenues from veterinary applications and is finalizing a strategic joint venture for the veterinary development program.
Key Highlights
- Expanded CannEpil® license to include veterinary therapeutic applications.
- New royalty rates: 10% for veterinary applications, 15% for human applications.
- Targets companion-animal oncology and chronic pain management markets.
- Veterinary pain management market projected to reach $3.8B by 2030.
- Veterinary oncology market estimated between $900M and $1.7B.
- Pursuing FDA Center for Veterinary Medicine's INAD and Conditional Approval pathways.
- Finalizing strategic joint venture for CannEpil's veterinary development program.
- Extended various deadlines in the original License Agreement.
Price Impact
More from SBEV